Publications [#197945] of Daniel B. Mark

Papers Published

1. WC Levy, KL Lee, AS Hellkamp, JE Poole, D Mozaffarian, DT Linker, AP Maggioni, I Anand, PA Poole-Wilson, DP Fishbein, G Johnson, J Anderson, DB Mark, GH Bardy, Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population., Circulation, vol. 120 no. 10 (September, 2009), pp. 835-42, ISSN 1524-4539 [doi]
   (last updated on 2011/11/29)

   Abstract:
   BACKGROUND: Although implantable cardioverter-defibrillator (ICD) therapy reduces mortality in moderately symptomatic heart failure patients with an ejection fraction 20%), no benefit of ICD treatment was seen. Projected over each patient's predicted lifespan, ICD treatment added 6.3, 4.1, 3.0, 1.9, and 0.2 additional years of life in the lowest- to highest-risk groups, respectively. CONCLUSIONS: A clinical risk prediction model identified subsets of moderately symptomatic heart failure patients in SCD-HeFT in whom single-lead ICD therapy was of no benefit and other subsets in which benefit was substantial.

   Keywords:
   Adult • Amiodarone • Anti-Arrhythmia Agents • Death, Sudden, Cardiac • Defibrillators, Implantable* • Female • Heart Failure • Humans • Kaplan-Meier Estimate • Male • Middle Aged • Models, Statistical • Primary Prevention • Risk • complications* • etiology* • methods* • mortality • prevention & control* • therapeutic use • therapy*